Diaccurate Announces the Appointment of Scott Filosi as EVEXTA BIOCEO and Corporate Name Change to Evexta Bio Scott Filosi brings more than 30 years of experience in market access and commercialization of innovative medicines at a global level.New name reflects the company's focus on its innovative portfolio of drug candidates that push the boundaries of precision oncology.

Diaccurate宣布任命Scott Filosi作为EVEXTA BIOCEO，公司名称更改为EVEXTA Bio Scott Filosi，在全球范围内为创新药物的市场准入和商业化带来30多年的经验。新名称反映了该公司关注其创新的候选药物组合，推动了精准肿瘤学的界限。

Paris, France, November 6, 2023 - Diaccurate SA, a clinical-stage biotechnology company focused on developing targeted therapeutics in oncology, - announces the appointment of Scott Filosi as Chief Executive Officer (CEO), effective November 6, 2023. The company changes name to Evexta Bio, effective immediately.

法国巴黎，2023年11月6日-Diaccurate SA，一家专注于开发肿瘤靶向治疗药物的临床阶段生物技术公司，宣布Scott Filosi任命为首席执行官（CEO），自2023年11月6日起生效。公司将名称更改为Evexta Bio，立即生效。

Dominique Bridon, former CEO, is appointed Chief Scientific Officer, and will remain as an executive and Board Member. Scott is an experienced executive leader with an outstanding track record in the pharmaceutical and biotechnology sector and as CEO. Scott brings more than 30 years of experience where he has put on the market more than 20 innovative medicines.

前首席执行官Dominique Bridon被任命为首席科学官，并将继续担任执行官和董事会成员。斯科特是一位经验丰富的执行领导者，在制药和生物技术领域拥有出色的业绩并担任首席执行官。斯科特在市场上销售了20多种创新药物，拥有30多年的经验。

Scott served as CEO of Luzsana Bio and Mirror Bio where he helped to advance key clinical programs, raise capital and advance strategic imperatives. Prior to his CEO roles, Scott was successively global Senior Vice President Market Access and Pricing and Chief Commercial Officer US for Merck KGaA successfully launching multiple oncology assets and indications.

斯科特担任Luzsana Bio和Mirror Bio的首席执行官，帮助推进关键临床项目，筹集资金和推进战略需求。在担任首席执行官之前，斯科特先后担任全球高级副总裁市场准入和定价，美国首席商业官为默克公司成功推出了多种肿瘤资产和适应症。

He brings diverse experience in sales, marketing, market access, pricing, operations and business development with organizations including UCB, J&J and Boehringer-Ingelheim. The Annual General Meeting also approved the change of company name to Evexta Bio. designed to better represent the company’s ability to advance rupitasertib through Phase 2/3 development, and to collaborate.

他与包括UCB，J＆J和Boehringer Ingelheim在内的组织在销售，营销，市场准入，定价，运营和业务发展方面拥有丰富的经验。年度大会还批准将公司名称更改为Evexta Bio。旨在更好地代表公司通过2/3阶段开发推进rupitasertib的能力，并进行合作。

Attachment

附件

PR in English

英语公关